The association between the gut microbiome and antituberculosis drug-induced liver injury

作者：Shengfei Pei, Li Yang, Huixia Gao, Yuzhen Liu, Jianhua Lu, Erbin Dai, Chunyan Meng, Fumin Feng, Yuling Wang · 发表于：Frontiers in Pharmacology · 年份：2025 · DOI：10.3389/fphar.2025.1512815 · 被引用次数：4 · 研究领域：Drug-Induced Hepatotoxicity and Protection、Gut microbiota and health、Drug Transport and Resistance Mechanisms

Background This study aimed to explore the distinct characteristics of the gut microbiota in tuberculosis (TB) patients who experienced liver injury following anti-TB treatment compared with those who did not. Method We employed a nested case-control study design, recruiting newly diagnosed pulmonary TB patients at Tangshan Infectious Disease Hospital. Participants were categorized into the Antituberculosis Drug-Induced Liver Injury (ADLI) group and the Non-ADLI group based on the occurrence of liver injury after treatment. Both groups received identical anti-TB regimens. Stool samples were collected from patients who developed liver injury within 2–3 weeks of starting treatment, alongside matched controls during the same timeframe. The samples underwent 16S rDNA sequencing, and clinical data and blood samples were also collected for further analysis. At the same time, we constructed mouse models to explore the effects of different anti-tuberculosis drugs on gut microbiota. Results Following anti-TB treatment, we observed a decrease in microbial diversity and significant structural changes in the gut microbiota of TB patients (P < 0.05). At T1, the Non_ADLI_T1 group presented relatively high levels of Phascolarctobacterium , Anaerofustis and Mailhella . In contrast, the ADLI_ T1 group presented elevated levels of Bacteroides , Veillonella , Clavibacter , Corynebacterium , Anaerococcus , Gardnerella , Peptostreptococcus and Lautropia . At T2, the ADLI_T2 group presented...